Clinical Trial Update: Efficacy and Safety of Stannsoporfin in Neonates [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing efficacy and safety of stannsoporfin in neonates has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Nutritional and Metabolic Disorders

Drugs mentioned

• stannsoporfin (stannsoporfin)

Snippet

Sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | Conditions: Nutritional and Metabolic Diseases | Phase 3 | Status: COMPLETED